Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement